Portal de investigación
Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country
Fecha de publicación:
Autores organización
Autores
- Cifuentes C.
- Lombana M.
- Vargas H.
- Laguado P.
- Ruiz-Patiño A.
- Navarro U.
- Vargas C.
- Ricaurte L.
- Arrieta O.
- Zatarain-Barron L.
- Zapata L.
- González G.
- Ortiz C.
- Bernal L.
- Restrepo J.G.
- Viola L.
- Grosso F.
- Zapata R.
- Mantilla W.
- Carranza H.
- Bustillo I.
- Llinas N.
- Duarte R.
- Rodríguez J.
- Archila P.
- Ávila J.
- Bermúdez M.
- Gámez T.
- Sotelo C.
- Otero J.
- Forero E.
- Lema M.
- Limpias C.
- Ordóñez-Reyes C.
- Mejía S.
- Rolfo C.
- Rosell R.
Grupos de investigación
Resumen
Purpose: Identifying actionable oncogenic mutations have changed the therapeutic landscape in different types of tumors. This study investigated the utility of comprehensive genomic profiling (CGP), a hybrid capture-based next-generation sequencing (NGS) assay, in clinical practice in a developing country. Methods: In this retrospective cohort study, CGP was performed on clinical samples from patients with different solid tumors recruited between December 2016 and November 2020, using hybrid capture-based genomic profiling, at the individual treating physicians’ request in the clinical care for therapy decisions. Kaplan–Meier survival curves were estimated to characterize the time-to-event variables. Results: Patients median age was 61 years (range: 14–87 years), and 64.7% were female. The most common histological diagnosis was lung primary tumors, with 90 patients corresponding to 52.9% of the samples (95% CI 45.4-60.4%). Actionable mutations with FDA-approved medications for specific alterations correspondent to tumoral histology were identified in 58 cases (46.4%), whereas other alterations were detected in 47 different samples (37.6%). The median overall survival was 15.5 months (95% CI 11.7 months-NR). Patients who were subjected to genomic evaluation at diagnosis reached a median overall survival of 18.3 months (95% CI 14.9 months-NR) compared to 14.1 months (95% CI 11.1 months-NR) in patients who obtained genomic evaluation after tumor progression and during standard treatment (P =.7). Conclusion: CGP of different types of tumors identifies clinically relevant genomic alterations that have benefited from targeted therapy and improve cancer care in a developing country to guide personalized treatment to beneficial outcomes of cancer patients. © The Author(s) 2023.
Datos de la publicación
- ISSN/ISSNe:
- 1073-2748, 1526-2359
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 37148308
- Enlace a otro recurso:
- www.scopus.com
Cancer Control SAGE Publications Ltd
Citas Recibidas en Scopus: 3
Documentos
- No hay documentos
Filiaciones
Keywords
- Developing Countries; Female; Genomics; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Retrospective Studies; antineoplastic metal complex; atezolizumab; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; pembrolizumab; pemetrexed; adolescent; adult; aged; Article; cancer patient; cancer therapy; cohort analysis; comprehensive genomic profiling; controlled study; developing country; female; Food and Drug Administration; gene mutation; genetic profile; high throughput sequencing; histology; human; Kaplan Meier method; lung tumor; major clinical study; male; oncogenomics; overall survival; personalized medicine; primary tumor; retrospective study; solid tumor; tumor growth; developed country; genomics; high throughput sequencing; lung tumor; middle aged; mutation; pathology